Distributed intraclot thrombolysis: Mechanism of accelerated thrombolysis with encapsulated plasminogen activators

Jonathan K Leach, E. Patterson, Edgar A. O'Rear

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The delivery of encapsulated plasminogen activators has demonstrated enhanced thrombolysis in vivo in several models. The mechanism of such improvement has not previously been established. Objectives. We explored in vitro the mechanism by which microencapsulation of streptokinase in polymeric microparticles accelerates clot digestion and reduces reperfusion times by as much as an order of magnitude in vivo. Methods: The efficacy of microencapsulated streptokinase (MESK) was directly compared with identical dosages of unencapsulated streptokinase (FREE SK) at three initial pressure drops using clots formed of plasma or whole blood in 0.2-cm inner diameter glass capillary tubes. Results: MESK demonstrated accelerated flow restoration compared with FREE SK for each condition in plasma (23.8 ± 4.5% faster) and whole blood clots (17.2 ± 9.2% faster). Images collected by fight microscopy show sites of thrombolysis internal to the clot only with MESK while the spatial distribution of fluorescently labeled streptokinase by confocal microscopy confirms greater penetration of the encapsulated agent compared with unencapsulated streptokinase. Digestion thus proceeds in three dimensions rather than restricted to a two-dimensional lysis front. Conclusions: The improved clot penetration with MESK establishes enhanced transport with encapsulation and the concept of distributed intraclot thrombolysis as a basis for the accelerated dissolution observed with encapsulated plasminogen activators in vivo.

Original languageEnglish (US)
Pages (from-to)1548-1555
Number of pages8
JournalJournal of Thrombosis and Haemostasis
Volume2
Issue number9
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Streptokinase
Plasminogen Activators
Digestion
Drug Compounding
Confocal Microscopy
Reperfusion
Glass
Microscopy
Thrombosis
Pressure

Keywords

  • Drug delivery
  • Fibrinolysis
  • Ischemia
  • Streptokinase

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Distributed intraclot thrombolysis : Mechanism of accelerated thrombolysis with encapsulated plasminogen activators. / Leach, Jonathan K; Patterson, E.; O'Rear, Edgar A.

In: Journal of Thrombosis and Haemostasis, Vol. 2, No. 9, 09.2004, p. 1548-1555.

Research output: Contribution to journalArticle

@article{cbbc54e859e845508c6ff30810ad4116,
title = "Distributed intraclot thrombolysis: Mechanism of accelerated thrombolysis with encapsulated plasminogen activators",
abstract = "Background: The delivery of encapsulated plasminogen activators has demonstrated enhanced thrombolysis in vivo in several models. The mechanism of such improvement has not previously been established. Objectives. We explored in vitro the mechanism by which microencapsulation of streptokinase in polymeric microparticles accelerates clot digestion and reduces reperfusion times by as much as an order of magnitude in vivo. Methods: The efficacy of microencapsulated streptokinase (MESK) was directly compared with identical dosages of unencapsulated streptokinase (FREE SK) at three initial pressure drops using clots formed of plasma or whole blood in 0.2-cm inner diameter glass capillary tubes. Results: MESK demonstrated accelerated flow restoration compared with FREE SK for each condition in plasma (23.8 ± 4.5{\%} faster) and whole blood clots (17.2 ± 9.2{\%} faster). Images collected by fight microscopy show sites of thrombolysis internal to the clot only with MESK while the spatial distribution of fluorescently labeled streptokinase by confocal microscopy confirms greater penetration of the encapsulated agent compared with unencapsulated streptokinase. Digestion thus proceeds in three dimensions rather than restricted to a two-dimensional lysis front. Conclusions: The improved clot penetration with MESK establishes enhanced transport with encapsulation and the concept of distributed intraclot thrombolysis as a basis for the accelerated dissolution observed with encapsulated plasminogen activators in vivo.",
keywords = "Drug delivery, Fibrinolysis, Ischemia, Streptokinase",
author = "Leach, {Jonathan K} and E. Patterson and O'Rear, {Edgar A.}",
year = "2004",
month = "9",
doi = "10.1111/j.1538-7836.2004.00884.x",
language = "English (US)",
volume = "2",
pages = "1548--1555",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Distributed intraclot thrombolysis

T2 - Mechanism of accelerated thrombolysis with encapsulated plasminogen activators

AU - Leach, Jonathan K

AU - Patterson, E.

AU - O'Rear, Edgar A.

PY - 2004/9

Y1 - 2004/9

N2 - Background: The delivery of encapsulated plasminogen activators has demonstrated enhanced thrombolysis in vivo in several models. The mechanism of such improvement has not previously been established. Objectives. We explored in vitro the mechanism by which microencapsulation of streptokinase in polymeric microparticles accelerates clot digestion and reduces reperfusion times by as much as an order of magnitude in vivo. Methods: The efficacy of microencapsulated streptokinase (MESK) was directly compared with identical dosages of unencapsulated streptokinase (FREE SK) at three initial pressure drops using clots formed of plasma or whole blood in 0.2-cm inner diameter glass capillary tubes. Results: MESK demonstrated accelerated flow restoration compared with FREE SK for each condition in plasma (23.8 ± 4.5% faster) and whole blood clots (17.2 ± 9.2% faster). Images collected by fight microscopy show sites of thrombolysis internal to the clot only with MESK while the spatial distribution of fluorescently labeled streptokinase by confocal microscopy confirms greater penetration of the encapsulated agent compared with unencapsulated streptokinase. Digestion thus proceeds in three dimensions rather than restricted to a two-dimensional lysis front. Conclusions: The improved clot penetration with MESK establishes enhanced transport with encapsulation and the concept of distributed intraclot thrombolysis as a basis for the accelerated dissolution observed with encapsulated plasminogen activators in vivo.

AB - Background: The delivery of encapsulated plasminogen activators has demonstrated enhanced thrombolysis in vivo in several models. The mechanism of such improvement has not previously been established. Objectives. We explored in vitro the mechanism by which microencapsulation of streptokinase in polymeric microparticles accelerates clot digestion and reduces reperfusion times by as much as an order of magnitude in vivo. Methods: The efficacy of microencapsulated streptokinase (MESK) was directly compared with identical dosages of unencapsulated streptokinase (FREE SK) at three initial pressure drops using clots formed of plasma or whole blood in 0.2-cm inner diameter glass capillary tubes. Results: MESK demonstrated accelerated flow restoration compared with FREE SK for each condition in plasma (23.8 ± 4.5% faster) and whole blood clots (17.2 ± 9.2% faster). Images collected by fight microscopy show sites of thrombolysis internal to the clot only with MESK while the spatial distribution of fluorescently labeled streptokinase by confocal microscopy confirms greater penetration of the encapsulated agent compared with unencapsulated streptokinase. Digestion thus proceeds in three dimensions rather than restricted to a two-dimensional lysis front. Conclusions: The improved clot penetration with MESK establishes enhanced transport with encapsulation and the concept of distributed intraclot thrombolysis as a basis for the accelerated dissolution observed with encapsulated plasminogen activators in vivo.

KW - Drug delivery

KW - Fibrinolysis

KW - Ischemia

KW - Streptokinase

UR - http://www.scopus.com/inward/record.url?scp=13244250992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244250992&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2004.00884.x

DO - 10.1111/j.1538-7836.2004.00884.x

M3 - Article

C2 - 15333029

AN - SCOPUS:13244250992

VL - 2

SP - 1548

EP - 1555

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -